<DOC>
	<DOCNO>NCT00982007</DOCNO>
	<brief_summary>The main objective study demonstrate efficacy safety investigational intravenous ( IV ) iron , ferric carboxymaltose ( FCM ) , compare oral iron subject iron deficiency anemia ( IDA ) show unsatisfactory response oral iron .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Ferric Carboxymaltose ( FCM ) Patients With Iron Deficiency Anemia ( IDA )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female subject ≥ 18 year age able give inform consent . Diagnosis Iron Deficiency Anemia ( IDA ) . Hemoglobin ( Hgb ) ≤ 11 g/dL . Ferritin ≤ 100 ng/mL ≤ 300 Transferrin Saturation ( TSAT ) ≤ 30 % . Must demonstrate unsatisfactory response intolerance oral iron . Known hypersensitivity reaction component ferric carboxymaltose ferrous sulfate . Previously randomize clinical study Ferric Carboxymaltose ( FCM ) . Requires dialysis treatment chronic kidney disease . No evidence iron deficiency . Any nonviral infection . AST ALT screen 1 , determine central lab , great 1.5 time upper limit normal . Known positive hepatitis evidence active disease . Received investigational drug within 30 day screen . Alcohol drug abuse within past 6 month . Hemochromatosis iron storage disorder . Estimated life expectancy le 6 month , cancer patient , ECOG Performance Status great 1 . Any laboratory abnormality , medical condition , psychiatric disorder opinion investigator would put subject 's disease management risk may result subject unable comply study requirement . Pregnant sexuallyactive female childbearing potential willing use acceptable form contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>IDA</keyword>
</DOC>